Literature DB >> 1348999

Management of massive upper gastrointestinal haemorrhage from multiple sites of peptic ulceration with somatostatin and octreotide--a report of five cases.

S A Jenkins1, B A Taylor, D M Nott, S Ellenbogen, J Haggie, R Shields.   

Abstract

Surgical management of massive upper gastrointestinal bleeding after failed medical treatment may be hazardous because of diffuse bleeding from several sites, further complicated in some patients by intercurrent disease, age, or previous surgery. Experience with combined somatostatin and octreotide therapy in five such patients is described. All were treated initially with either intravenous somatostatin (250 micrograms/hour) or octreotide (Sandostatin) (50 micrograms/hour) for periods ranging from three to five days, after which they were given subcutaneous octreotide (50 or 100 micrograms three times daily). Bleeding was controlled by this regimen in all cases. The patients were all discharged from hospital on either ranitidine (n = 4) or omeprazole (n = 1). Repeat endoscopy at the end of the treatment period with somatostatin and octreotide (n = 1) or four weeks after discharge (n = 3) showed complete healing of the bleeding sites. Somatostatin and octreotide may be of value in controlling severe upper gastrointestinal bleeding in patients in whom surgery is hazardous because of bleeding from several peptic lesions further complicated in some by intercurrent disease or age.

Entities:  

Mesh:

Substances:

Year:  1992        PMID: 1348999      PMCID: PMC1373838          DOI: 10.1136/gut.33.3.404

Source DB:  PubMed          Journal:  Gut        ISSN: 0017-5749            Impact factor:   23.059


  9 in total

1.  Somatostatin compared with cimetidine in the treatment of bleeding peptic ulcer without visible vessel.

Authors:  E Saperas; J M Piqué; R Pérez-Ayuso; F Fuster; J Terés; J M Bordas; J Rodés
Journal:  Aliment Pharmacol Ther       Date:  1988-04       Impact factor: 8.171

2.  Clinical factors in the prediction of further haemorrhage or mortality in acute upper gastrointestinal haemorrhage.

Authors:  A E Clason; D A Macleod; R A Elton
Journal:  Br J Surg       Date:  1986-12       Impact factor: 6.939

3.  Stigmata of recent haemorrhage in diagnosis and prognosis of upper gastrointestinal bleeding.

Authors:  D N Foster; K J Miloszewski; M S Losowsky
Journal:  Br Med J       Date:  1978-05-06

4.  Optimal timing of operation for bleeding peptic ulcer: prospective randomised trial.

Authors:  D L Morris; P C Hawker; S Brearley; M Simms; P W Dykes; M R Keighley
Journal:  Br Med J (Clin Res Ed)       Date:  1984-04-28

5.  Placebo-controlled trial with the somatostatin analogue SMS 201-995 in peptic ulcer bleeding.

Authors:  J Christiansen; R Ottenjann; F Von Arx
Journal:  Gastroenterology       Date:  1989-09       Impact factor: 22.682

6.  Somatostatin in treatment of haematemesis and melaena.

Authors:  K W Somerville; D A Henry; J G Davies; K R Hine; C J Hawkey; M J Langman
Journal:  Lancet       Date:  1985-01-19       Impact factor: 79.321

7.  Randomised double blind trial of somatostatin in the treatment of massive upper gastrointestinal haemorrhage.

Authors:  I Magnusson; T Ihre; C Johansson; U Seligson; S Törngren; K Uvnäs-Moberg
Journal:  Gut       Date:  1985-03       Impact factor: 23.059

8.  Somatostatin and cimetidine in the control of acute upper gastrointestinal bleeding. A controlled multicenter study.

Authors:  A Antonioli; M Gandolfo; G P Rigo; G Bianchi Porro; R Cheli; F Brancato; M Lazzaroni; M C Parodi; A Maringhini; S Raimondo
Journal:  Hepatogastroenterology       Date:  1986-04

9.  Ranitidine and somatostatin. Their effects on bleeding from the upper gastrointestinal tract.

Authors:  N Basso; M Bagarani; F Bracci; G Cucchiara; D Gizzonio; G Grassini; M Percoco; F Procacciante; F Toti
Journal:  Arch Surg       Date:  1986-07
  9 in total
  2 in total

Review 1.  Octreotide's role in the management of sulfonylurea-induced hypoglycemia.

Authors:  Patrick P Dougherty; Wendy Klein-Schwartz
Journal:  J Med Toxicol       Date:  2010-06

2.  Therapeutic applications of octreotide in pediatric patients.

Authors:  Abdulrahman Al-Hussaini; Decker Butzner
Journal:  Saudi J Gastroenterol       Date:  2012 Mar-Apr       Impact factor: 2.485

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.